[1]
|
Seow, W.J., Matsuo, K., Hsiung, C.A., et al. (2017) Association between GWAS-Identified Lung Adenocarcinoma Susceptibility Loci and EGFR Mutations in Never-Smoking Asian Women, and Comparison with Findings from Western Populations. Human Molecular Genetics, 26, 454-465.
|
[2]
|
Da Cunha Santos, G., Shepherd, F.A. and Tsao, M.S. (2011) EGFR Mutations and Lung Cancer. Annual Review of Pathology, 6, 49-69. https://doi.org/10.1146/annurev-pathol-011110-130206
|
[3]
|
Bao, M.X., Jing, C. and Duan, D. (2005) Identification of EGFR Kinase Domain Mutations among Lung Cancer Patients in China: Implication for Targeted Cancer Therapy. Cell Research, 15, 212. https://doi.org/10.1038/sj.cr.7290289
|
[4]
|
Yuh, M. (2013) Usage of EGFR-TKI and WBRT in NSCLC Patients with Brain Metastases. Annals of Palliative Medicine, 2, 108-110.
|
[5]
|
Fan, Y., Xu, X. and Xie, C. (2014) EGFR-TKI Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: A Pooled Analysis of Published Data. OncoTargets and Therapy, 7, 2075-2084. https://doi.org/10.2147/OTT.S67586
|
[6]
|
Roskoski, R. (2019) Small Molecule Inhibitors Targeting the EGFR/ErbB Family of Protein-Tyrosine Kinases in Human Cancers. Pharmacological Research, 139, 395-411. https://doi.org/10.1016/j.phrs.2018.11.014
|
[7]
|
Li, Y., Appius, A., Pattipaka, T., et al. (2019) Real-World Management of Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small-Cell Lung Cancer in the USA. PLoS ONE, 14, e0209709. https://doi.org/10.1371/journal.pone.0209709
|
[8]
|
Ahn, M.J., Kim, S.W., Cho, B.C., et al. (2014) Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea with Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR. Oncologist, 19, 702-703. https://doi.org/10.1634/theoncologist.2013-0419
|
[9]
|
Schuette, W., Schirmacher, P., Eberhardt, W.E., et al. (2015) EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non-Small Cell Lung Cancer in Germany: An Observational Study. Cancer Epidemiology, Biomarkers & Prevention, 24, 1254-1261. https://doi.org/10.1158/1055-9965.EPI-14-1149
|
[10]
|
Chen, W., Zheng, R., Zeng, H., et al. (2015) Epidemiology of Lung Cancer in China. Thoracic Cancer, 6, 209-215. https://doi.org/10.1111/1759-7714.12169
|
[11]
|
Agustoni, F., Suda, K., Yu, H., et al. (2019) EGFR-Directed Monoclonal Antibodies in Combination with Chemotherapy for Treatment of Non-Small-Cell Lung Cancer: An Updated Review of Clinical Trials and New Perspectives in Biomarkers Analysis. Cancer Treatment Reviews, 72, 15-27. https://doi.org/10.1016/j.ctrv.2018.08.002
|
[12]
|
Takanashi, Y., Tajima, S., Hayakawa, T., et al. (2016) Pulmonary Micropapillary-Type Adenosquamous Carcinoma Sharing Epidermal Growth Factor Receptor Mutation in Adenocarcinoma and Squamous Cell Carcinoma. Respirology Case Reports, 4, e00179. https://doi.org/10.1002/rcr2.179
|
[13]
|
Wang, Z., Li, Z., Ding, X., et al. (2015) ERbeta Localization Influenced Outcomes of EGFR-TKI Treatment in NSCLC Patients with EGFR Mutations. Scientific Reports, 5, 11392. https://doi.org/10.1038/srep11392
|
[14]
|
Sasaki, H., Endo, K., Mizuno, K., et al. (2006) EGFR Mutation Status and Prognosis for Gefitinib Treatment in Japanese Lung Cancer. Lung Cancer, 51, 135-136. https://doi.org/10.1016/j.lungcan.2005.09.004
|
[15]
|
Zhong, W.-Z., Wang, Q., Mao, W.-M., et al. (2018) Gefitinib versus Vinorelbine plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC (ADJUVANT/CTONG1104): A Randomised, Open-Label, Phase 3 Study. The Lancet Oncology, 19, 139-148. https://doi.org/10.1016/S1470-2045(17)30729-5
|
[16]
|
Kuiper, J.L., Hashemi, S.M., Thunnissen, E., et al. (2016) Non-Classic EGFR Mutations in a Cohort of Dutch EGFR-Mutated NSCLC Patients and Outcomes Following EGFR-TKI Treatment. British Journal of Cancer, 115, 1504-1512. https://doi.org/10.1038/bjc.2016.372
|
[17]
|
Soo, R.A., Kubo, A., Ando, M., et al. (2017) Association between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-Smokers with Non-Small-Cell Lung Cancer: Analyses from a Prospective Multinational ETS Registry. Clinical Lung Cancer, 18, 535-542. https://doi.org/10.1016/j.cllc.2017.01.005
|
[18]
|
Kawaguchi, T., Ando, M., Kubo, A., et al. (2011) Long Exposure of Environmental Tobacco Smoke Associated with Activating EGFR Mutations in Never-Smokers with Non-Small Cell Lung Cancer. Clinical Cancer Research, 17, 39-45. https://doi.org/10.1158/1078-0432.CCR-10-1773
|
[19]
|
Shi, Y., Siu-Kie Au, J., Thongprasert, S., Chun-Ming, T.M., Karin Heeroma, T.K., et al. (2014) A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). Journal of Thoracic Oncology, 9, 154-156. https://doi.org/10.1097/JTO.0000000000000033
|
[20]
|
Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[21]
|
Penault-Llorca, F. and Radosevic-Robin, N. (2018) Tumor Mutational Burden in Non-Small Cell Lung Cancer-The Pathologist’s Point of View. Translational Lung Cancer Research, 7, 716-721. https://doi.org/10.21037/tlcr.2018.09.26
|
[22]
|
Li, M., Zhang, Q., Liu, L., et al. (2011) The Different Clinical Significance of EGFR Mutations in Exon 19 and 21 in Non-Small Cell Lung Cancer Patients of China. Neoplasma, 58, 74-81. https://doi.org/10.4149/neo_2011_01_74
|
[23]
|
Wu, Y.-L., Lee, V., Liam, C.-K., et al. (2018) Clinical Utility of a Blood-Based EGFR Mutation Test in Patients Receiving First-Line Erlotinib Therapy in the ENSURE, FASTACT-2, and ASPIRATION Studies. Lung Cancer, 126, 1-8. https://doi.org/10.1016/j.lungcan.2018.10.004
|
[24]
|
Benbrahim, Z., Antonia, T. and Mellas, N. (2018) EGFR Mutation Frequency in Middle East and African Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis. BMC Cancer, 18, 891. https://doi.org/10.1186/s12885-018-4774-y
|
[25]
|
Yang, M.Z., Zhang, L., Bai, J., et al. (2016) The Difference of EGFR Mutation in Uygur and Han’s Non-Small Cell Lung Cancer in Xinjiang, China. Modern Oncology, 24, 404-406.
|
[26]
|
Gu, G.D., Wang, X. and Liu, C. (2014) Clinical Feature Analysis of 254 Cases of Uygur Lung Cancer Patients in Xinjiang Area. Journal of Clinical Medicine in Practice, 18, 37-38.
|